Are Peptides Legal in the EU and Bulgaria?
EU law requires a marketing authorisation before a medicinal product is placed on the market. What that means for unapproved peptides, and for Bulgaria.
Most writing about peptide legality is written about the United States, and then read by people who do not live there. The FDA’s compounding lists, the 503A categories, the July 2026 advisory vote — none of that is European law, and none of it has any effect in an EU Member State.
European law asks a different question, and the answer it gives is narrower.
The question EU law actually asks
It does not ask whether a substance is dangerous, or novel, or sold online. It asks whether the thing in front of it is a medicinal product, and if so, whether it has an authorisation.
The definition has two limbs, and either one is enough. A substance is a medicinal product if it is presented as having properties for treating or preventing disease, or if it may be used to restore, correct or modify physiological functions through pharmacological, immunological or metabolic action.
That second limb is why “research use only” does not work as a legal shield. The classification follows composition and use, not the disclaimer a seller prints on the vial. If a product is marketed with claims about healing, recovery, appetite or ageing, the first limb is engaged by the marketing itself.
Once something is a medicinal product, Article 6(1) of Directive 2001/83/EC applies. In its own words:
No medicinal product may be placed on the market of a Member State unless a marketing authorisation has been issued by the competent authorities of that Member State in accordance with this Directive or an authorisation has been granted in accordance with Regulation (EC) No 726/2004.
There is no shortage exemption in that sentence, no compounding list, and no research-use carve-out. Either an authorisation exists or the product may not be placed on the market.
What that means compound by compound
The consequence is simpler than the American picture, and less forgiving.
| Compound | EU position |
|---|---|
| Semaglutide, tirzepatide | Centrally authorised through the EMA. Lawful as the authorised product, on prescription |
| Tesamorelin | An approved medicine in the US; availability in the EU depends on national authorisation status |
| Semax | Registered in Russia. Never assessed by the EMA, so no EU authorisation exists |
| BPC-157, TB-500, KPV, MOTS-c, Epitalon | No marketing authorisation anywhere in the EU |
The July 2026 FDA committee vote changed nothing in this table. That process concerns which ingredients an American pharmacy may compound with, and it is frequently misreported even on its own terms.
Bulgaria specifically
Bulgaria applies the EU framework through the Закон за лекарствените продукти в хуманната медицина — the Medicinal Products in Human Medicine Act — supervised by the Изпълнителна агенция по лекарствата, the Bulgarian Drug Agency.
The part most relevant here is that an unauthorised medicine is not simply prohibited outright. There is a defined route, and its shape is the point.
Наредба № 10 of 17 November 2011 sets the conditions and procedure for treating patients with medicinal products that are not authorised in Bulgaria, for products used outside the terms of their authorisation, and for compassionate use. It also governs the list under Article 266а(2) of the Act.
What matters about that route is where it runs. Access is through a лечебно заведение — a licensed healthcare establishment — on a named-patient basis, with supply ordered through that institution. It is a clinical pathway with institutional gatekeeping and documentation, not a mechanism for an individual to buy an unauthorised product directly.
So the honest summary for Bulgaria is: a legal route for unauthorised medicines exists, and it is a hospital route. A private purchase from an online seller is not that route, and does not become it.
This is a description of the regulatory framework, not legal advice, and it deliberately stops short of the question people usually want answered. Whether an individual purchase creates personal liability, how customs treats a particular shipment, and how enforcement works in practice are separate questions that vary between Member States. Those need a qualified lawyer, not an article.
Why the American news does not transfer
Three differences are worth holding onto, because conflating them is the single most common error in this area.
There is no EU equivalent of the 503A bulks list. Pharmacy preparation exists in Europe, but it is a narrower national concept and it does not run through a federal list of nominated bulk substances.
Authorisation is jurisdictional. Semax being registered in Russia has no bearing on its status in Sofia. Approval is a decision by a specific regulator for a specific market, and it is not a global verdict on a molecule.
A shortage list is not a legal category here. The mechanism that made compounded semaglutide available in the US for two years — and then stopped — has no European counterpart.
What does not depend on any of this
The regulatory position varies by country and changes with time. The physical questions do not.
A lyophilised peptide degrades the same way in Sofia as in Chicago, on the timescales set out in storage. The relationship between milligrams in a vial, millilitres of diluent and marks on a syringe is arithmetic, and the calculator performs it identically regardless of where you are.
That is the part of this subject where a definite answer is available, which is also why it is the part this site actually helps with.
Frequently asked questions
Are unapproved peptides legal to sell in the EU?
Not as medicines. Article 6(1) of Directive 2001/83/EC provides that no medicinal product may be placed on the market of a Member State without a marketing authorisation issued by that state or granted centrally under Regulation (EC) No 726/2004. A peptide that meets the definition of a medicinal product and has no authorisation cannot lawfully be placed on the market.
Does labelling something "research use only" change its legal status?
No. Whether something is a medicinal product under EU law turns on its composition and on how it is presented or used — a substance presented as treating or preventing disease, or used to modify physiological functions through pharmacological, immunological or metabolic action. A disclaimer printed by the seller does not decide the classification.
How can an unauthorised medicine be used in Bulgaria at all?
Through a defined route rather than a private purchase. Наредба № 10 of 17 November 2011 sets the conditions and procedure for treating patients with medicinal products not authorised in Bulgaria, and access runs through a лечебно заведение — a licensed healthcare establishment — rather than directly to an individual.
Is buying peptides for personal use a criminal matter?
That is a question for a qualified lawyer in your jurisdiction, and this article does not answer it. What is set out here is the regulatory position on authorisation and supply. Personal liability, customs treatment and enforcement practice are separate matters that vary between Member States.
Sources
- Directive 2001/83/EC — Community code relating to medicinal products for human use (consolidated)
- Regulation (EC) No 726/2004 — Union procedures for the authorisation and supervision of medicinal products
- Наредба № 10 от 17 ноември 2011 г. — treatment with medicinal products not authorised in Bulgaria (Ministry of Health)
- Bulgarian Drug Agency (Изпълнителна агенция по лекарствата)
- European Medicines Agency — Medicines